New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month, compared with once a week for other obesity drugs like Wegovy and Zepbound that are already on the market.
Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...
In the case of Amgen (NASDAQ:AMGN), I can honestly say I knew very little about the stock beyond its name and sector for a ...
Goldman Sachs analyst Salveen Richter has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday.Don't Miss our Black ...
The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...
Wait for longer-term data with Amgen's GLP-1, says Piper Sandler's Christopher Raymond ...
Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...
Shares of General Motors and Ford fall after President-elect Donald Trump announces his tariff plans, while Amgen tumbles as ...
Stocks were higher Tuesday afternoon as investors digested earnings reports from several retailers and awaited results from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback